RJSBiologics
RJSBio strives to better serve cancer patients by providing promising new targeted drugs that may help make their cancer treatments more predictable. Please contact stephen.mccraith@rjsbiologics.com
We focus on removing known liabilities from cancer drugs associated with off-target effects. We have developed a novel drug conjugate approach that uses computationally designed affinity tags to drive therapeutic compounds into cancer cells. This novel targeted approach is anticipated to improve the predictability of cancer drug development.
Our affinity tags facilitate effective tumor cell uptake of conjugated drugs by allowing drugs to be ferried into cancer cells using cancer proteins. Our design minimizes unwanted uptake of these drugs by normal cells, where harmful side effects are manifested. RJS Biologics’ innovative approach should be broadly applicable to many cancer drugs.
Products / Services
BioPharmaceuticals Sectors: Oncology and Anti-Inflammatory
We have developed a novel drug conjugate approach that uses computationally designed affinity tags to drive therapeutic compounds into cancer cells. This novel targeted approach is anticipated to improve the predictability of cancer drug development. Our affinity tags facilitate effective tumor cell uptake of conjugated drugs by allowing drugs to be ferried into cancer cells using cancer proteins. We strive to minimize unwanted uptake of these drugs by normal cells. RJS Biologics’ innovative approach should be broadly applicable to many cancer drugs.
RJSBio strives to better serve cancer patients by providing promising new targeted drugs that may help make their cancer treatments more predictable. Please contact stephen.mccraith@rjsbiologics.com.
See Campaign: https://www.equitynet.com/c/rjsbiologics?s=p
Contact Information:
Stephen McCraith
Tags:
EquityNet, Equity, United States, Drugs, English, Pharmaceuticals & Biotech, Industry verticals, Regions, Types of Crowdfunding deal, Language, Washington
Source: ICNW